Evidence map›Paper›PMID 31788461›Full record

ArticleFrontiers in pediatrics2019

Progressive Liver Disease in Patients With Ataxia Telangiectasia.

Helena Donath, Sandra Woelke, Marius Theis, Ursula Heß, Viola Knop, Eva Herrmann, Dorothea Krauskopf, Matthias Kieslich, Ralf Schubert, Stefan Zielen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Plasma Copper and Zinc Levels in Ataxia-Telangiectasia.International journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Movement Disorders and the Gut: A Review.Movement disorders clinical practice · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Helena DonathDivision of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany.
Sandra WoelkeDivision of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany.
Marius TheisDivision of Pediatric Neurology, Department for Children and Adolescents, Goethe University, Frankfurt, Germany.
Ursula HeßDivision of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany.
Viola KnopDepartment for Internal Medicine, Goethe University, Frankfurt, Germany.
Eva HerrmannInstitute of Biostatistics and Mathematical Modeling, Goethe University, Frankfurt, Germany.
Dorothea KrauskopfDivision of Pediatric Neurology, Department for Children and Adolescents, Goethe University, Frankfurt, Germany.
Matthias KieslichDivision of Pediatric Neurology, Department for Children and Adolescents, Goethe University, Frankfurt, Germany.
Ralf SchubertDivision of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany.
Stefan ZielenDivision of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany.
Goethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia, immunodeficiency, genetic instability, premature aging and growth retardation. Due to better care the patients get older than in the past and new disease entities like disturbed glucose tolerance and liver disease emerge. The objective of the present investigation is to determine the evolution of liver disease and its relation to age and neurological deterioration. The study included 67 patients aged 1 to 38 years with classical A-T. At least two measurements of liver enzymes were performed within a minimum interval of 6 months in 56 patients. The median follow-up period was 4 years (1-16 years). A total of 316 liver enzyme measurements were performed. For analysis, patients were divided into two age groups (Group 1: <12 years; group 2: ≥12 years). In addition, ultrasound of the liver and Klockgether Ataxia Score (KAS) were analyzed. We found significantly higher levels of alpha-fetoprotein (AFP) (226,8 ± 20.87 ng/ml vs. 565,1 ± 24.3 ng/ml,

Indexed as

ataxia scoreAtaxia telangiectasiahepatic steatosisliver diseaseneurodegeneration

Identifiers

PMID31788461
PMCPMC6856634
OpenAlexW2988922430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.